Skip to main content

Our mission

We strive to discover and develop truly effective therapeutics for neurodegenerative diseases.

Our Team

We are a passionate team of scientists and drug developers dedicated to improving the lives of patients affected by neurodegenerative diseases.

Our R&D pipeline

Our pipeline of innovative small molecules has the potential to halt and prevent neurodegeneration in certain brain diseases.

Asceneuron discovers and develops groundbreaking therapeutics for neurodegenerative disorders with high unmet medical needs:
orphan tauopathies, Alzheimer’s and Parkinson’s diseases.

News & Events

- Press releases

Asceneuron Joins CPAD Consortium

Asceneuron Joins Critical Path for Alzheimer’s Disease Consortium

- Press releases

Asceneuron Expands Scientific Advisory Board

Asceneuron Expands Scientific Advisory Board with World Leading Experts in Neurodegenerative Diseases

- Press releases

Abbas Hussain Appointed as Chair of Asceneuron

Industry Veteran Abbas Hussain Appointed as Chair of Asceneuron

- Press releases

Asceneuron Welcomes Barbara Angehrn Pavik as New CEO

Asceneuron Welcomes Barbara Angehrn Pavik as New CEO as It Gears Up for Next Phase of Growth

- Event

Asceneuron to attend BIO International Convention in Boston

The Asceneuron team will attend the BIO International Convention to be held June 5-8 in Boston, MA.

- Event

Asceneuron will present at AD/PD 2023

The Asceneuron team will attend AD/PD 2023, the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders. from...

- Event

Asceneuron to attend Bio-Europe Spring event

Asceneuron's CEO Dirk Beher will attend the Bio Europe Spring partnering event held on March 20-22, 2023 in Basel, Switzerland.

- Press releases

Ferrer acquires worldwide rights to ASN90, exclusively to treat PSP

Ferrer acquires worldwide rights to ASN90, an O-GlcNAcase inhibitor from Asceneuron, exclusively to treat Progressive Supranuclear Palsy (PSP)

- Event

Asceneuron at the Annual Biotech in Europe Forum

Asceneuron will participate in the 22nd Annual Biotech in Europe Forum for global partnering and investment (BEF), being held on...